Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)EBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Zevra Therapeutics (ZVRA) Cost of Revenue (2019 - 2025)

Zevra Therapeutics' Cost of Revenue history spans 6 years, with the latest figure at $1.5 million for Q4 2025.

  • For Q4 2025, Cost of Revenue rose 11.27% year-over-year to $1.5 million; the TTM value through Dec 2025 reached $16.5 million, up 122.22%, while the annual FY2025 figure was $16.5 million, 122.22% up from the prior year.
  • Cost of Revenue reached $1.5 million in Q4 2025 per ZVRA's latest filing, up from $1.2 million in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $12.4 million in Q2 2025 to a low of $8000.0 in Q1 2022.
  • Average Cost of Revenue over 5 years is $1.5 million, with a median of $838500.0 recorded in 2021.
  • Peak YoY movement for Cost of Revenue: crashed 96.9% in 2022, then skyrocketed 2083.87% in 2023.
  • A 5-year view of Cost of Revenue shows it stood at $59000.0 in 2021, then skyrocketed by 157.63% to $152000.0 in 2022, then skyrocketed by 707.24% to $1.2 million in 2023, then increased by 11.33% to $1.4 million in 2024, then increased by 11.27% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for ZVRA's Cost of Revenue are $1.5 million (Q4 2025), $1.2 million (Q3 2025), and $12.4 million (Q2 2025).